JP2006526006A - トレミフェン結晶化法 - Google Patents
トレミフェン結晶化法 Download PDFInfo
- Publication number
- JP2006526006A JP2006526006A JP2006508327A JP2006508327A JP2006526006A JP 2006526006 A JP2006526006 A JP 2006526006A JP 2006508327 A JP2006508327 A JP 2006508327A JP 2006508327 A JP2006508327 A JP 2006508327A JP 2006526006 A JP2006526006 A JP 2006526006A
- Authority
- JP
- Japan
- Prior art keywords
- toremifene
- solvent
- mixture
- isomer
- acetone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 title claims abstract description 41
- 229960005026 toremifene Drugs 0.000 title claims abstract description 27
- 238000002425 crystallisation Methods 0.000 title description 15
- 239000002904 solvent Substances 0.000 claims abstract description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 42
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 31
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims abstract description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims description 3
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 claims description 2
- 229960004167 toremifene citrate Drugs 0.000 claims description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 230000008025 crystallization Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 238000001816 cooling Methods 0.000 description 9
- 238000009835 boiling Methods 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001833 anti-estrogenic effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- XFCLJVABOIYOMF-UHFFFAOYSA-N 2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine Chemical compound C1=CC(OCCN(C)C)=CC=C1C(C=1C=CC=CC=1)=C(CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CILUUGLLYLAHMG-UHFFFAOYSA-N 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,2-diphenylbutane-1,4-diol Chemical compound C1=CC(OCCN(C)C)=CC=C1C(O)(C=1C=CC=CC=1)C(CCO)C1=CC=CC=C1 CILUUGLLYLAHMG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- MKYQPGPNVYRMHI-UHFFFAOYSA-N Triphenylethylene Chemical group C=1C=CC=CC=1C=C(C=1C=CC=CC=1)C1=CC=CC=C1 MKYQPGPNVYRMHI-UHFFFAOYSA-N 0.000 description 1
- -1 and (d) optionally Chemical compound 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、トレミフェンおよびそれに対応するE異性体を含むいくつかの混合物から、トレミフェンを単離する方法を提供する。そのようなZおよびE異性体の混合物は、たとえば、米国特許第4,696,949号にて記載された種々の方法を用いて得ることができる。この異性体の混合物は、大量の他の物質を含まないことが好ましい。この異性体の混合物が、蒸留、濾過または遠心工程の残渣であることが好適である。
1−[4−(2−ジメチルアミノエトキシ)フェニル]−1,2−ジフェニルブタン−1,4−ジオール65gを、トルエン515mlに加えた。トルエン40mlを、常圧にて混合液より蒸留した。ついで、この混合液を−7±3℃まで冷却した。混合液を−7±3℃に維持しながら、塩化チオニル35mlを5±1時間かけて加えた。混合液を、−2±3℃にて1時間撹拌し、ついで3時間かけて80℃まで加熱した。ついで、この温度で4時間撹拌し続けた。混合液を50±5℃まで冷却し、水125mlおよび50%NaOH75mlを加えた。層を分離し、水層を捨てた。トルエン層を水80mlで洗浄した。トルエン層を冷却し、吸引下で蒸留した。メタノール(65ml)を残渣に加え、吸引下で蒸留した。蒸留残渣は、トレミフェン塩基およびそれに対応するE−異性体の混合物を含んでいた。メタノール195ml、セライト1gおよび活性炭1gを残渣に加え、メタノール15mlをこの混合液から蒸留した。熱混合液を加圧フィルター中で濾過し、セライト/チャコールケーキを沸騰メタノール10mlで洗浄した。洗浄メタノールおよび濾液をあわせ、沸騰するまで加熱した。この溶液を4時間かけて−7±3℃まで冷却し、3〜5時間撹拌した。沈殿物を濾過し、メタノール50mlで洗浄した。部分的に精製されたトレミフェン塩基を含む沈殿物を、沸騰するまで加熱することによりアセトン95mlに溶解した。この混合液を10時間かけて−10±3℃まで冷却して、生成物を結晶化した。結晶トレミフェン塩基を濾過し、アセトン30mlで洗浄した。生成物を50℃で、吸引にて乾燥させた。収量26.08g(40%)。
実施例1にて記載したように、メタノール結晶化により得られた部分的に精製されたトレミフェン塩基(5.0g)を、沸騰するまで加熱して、アセトン、メチルエチルケトンまたは酢酸エチル20mlに溶解し、実施例1の手順を用いて、13時間かけて−10℃まで冷却して結晶化した。結晶化トレミフェン塩基生成物の純度および色を以下に要約する。
Claims (9)
- トレミフェンまたはその薬学的に許容可能な塩を製造する方法であって、(a)トレミフェン塩基とそれに対応するE異性体との混合物を、メタノールを含む第一溶媒と接触させる工程、(b)トレミフェンを前記第一溶媒中で結晶化させる工程、(c)先の工程で結晶化された生成物を、アセトン、メチルエチルケトンまたは酢酸エチルを含む第二溶媒から結晶化させる工程、および(d)任意に、先の工程で結晶化されたトレミフェンを、その薬学的に許容可能な塩に変換する工程からなる方法。
- 前記第一溶媒が、少なくとも80重量%、好ましくは少なくとも90重量%、より好ましくは少なくとも95重量%のメタノールを含む請求項1記載の方法。
- 前記第二溶媒が、アセトンを含む請求項1記載の方法。
- 前記第二溶媒が、少なくとも80重量%、好ましくは少なくとも90重量%、より好ましくは少なくとも95重量%のアセトンを含む請求項3記載の方法。
- 前記第二溶媒が、メチルエチルケトンを含む請求項1記載の方法。
- 前記第二溶媒が、少なくとも80重量%、好ましくは少なくとも90重量%、より好ましくは少なくとも95重量%のメチルエチルケトンを含む請求項5記載の方法。
- 前記第二溶媒が、酢酸エチルを含む請求項1記載の方法。
- 前記第二溶媒が、少なくとも80重量%、好ましくは少なくとも90重量%、より好ましくは少なくとも95重量%の酢酸エチルを含む請求項7記載の方法。
- 前記薬学的に許容可能なトレミフェンの塩が、クエン酸トレミフェンである請求項1記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20030747A FI20030747A0 (fi) | 2003-05-19 | 2003-05-19 | Toremifeenin kiteytysmenetelmä |
PCT/FI2004/000304 WO2004101492A1 (en) | 2003-05-19 | 2004-05-19 | Toremifene crystallization method |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006526006A true JP2006526006A (ja) | 2006-11-16 |
JP4205130B2 JP4205130B2 (ja) | 2009-01-07 |
Family
ID=8566132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006508327A Expired - Lifetime JP4205130B2 (ja) | 2003-05-19 | 2004-05-19 | トレミフェン結晶化法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7368607B2 (ja) |
EP (1) | EP1625110A1 (ja) |
JP (1) | JP4205130B2 (ja) |
KR (1) | KR20060007027A (ja) |
CN (1) | CN100469759C (ja) |
CA (1) | CA2525835C (ja) |
FI (1) | FI20030747A0 (ja) |
IL (1) | IL171650A (ja) |
TW (1) | TWI332939B (ja) |
WO (1) | WO2004101492A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017507961A (ja) * | 2014-03-11 | 2017-03-23 | レプロス セラピューティクス インコーポレイティド | 単一の溶媒を用いるクロミフェン合成 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011013108A1 (en) | 2009-07-31 | 2011-02-03 | Ranbaxy Laboratories Limited | Polymorphic form of toremifene citrate and process for its preparation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI77839C (fi) | 1982-05-27 | 1989-05-10 | Farmos Oy | Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat. |
FI67538C (fi) * | 1982-05-27 | 1985-04-10 | Farmos Oy | Foerfarande foer framstaellning av (z)-1,2-difenyl-1-(4-(2-(n n-dimetylamino)etoxi)fenyl)-1-buten |
GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
US5491173A (en) | 1982-06-25 | 1996-02-13 | Orion-Yhtyma Oy | Tri-phenyl alkene derivatives and their preparation and use |
GR850899B (ja) | 1984-04-12 | 1985-11-25 | Gen Hospital Corp | |
US5011771A (en) * | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
FI109332B (fi) * | 1998-12-17 | 2002-07-15 | Orion Yhtymae Oyj | Toremifeenin liukoisia koostumuksia |
-
2003
- 2003-05-19 FI FI20030747A patent/FI20030747A0/fi unknown
-
2004
- 2004-05-14 TW TW093113639A patent/TWI332939B/zh active
- 2004-05-19 EP EP04733835A patent/EP1625110A1/en not_active Ceased
- 2004-05-19 CN CNB2004800120864A patent/CN100469759C/zh not_active Expired - Lifetime
- 2004-05-19 KR KR1020057019880A patent/KR20060007027A/ko active Search and Examination
- 2004-05-19 CA CA2525835A patent/CA2525835C/en not_active Expired - Lifetime
- 2004-05-19 US US10/557,471 patent/US7368607B2/en not_active Expired - Lifetime
- 2004-05-19 WO PCT/FI2004/000304 patent/WO2004101492A1/en active Application Filing
- 2004-05-19 JP JP2006508327A patent/JP4205130B2/ja not_active Expired - Lifetime
-
2005
- 2005-10-27 IL IL171650A patent/IL171650A/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017507961A (ja) * | 2014-03-11 | 2017-03-23 | レプロス セラピューティクス インコーポレイティド | 単一の溶媒を用いるクロミフェン合成 |
Also Published As
Publication number | Publication date |
---|---|
US7368607B2 (en) | 2008-05-06 |
CN100469759C (zh) | 2009-03-18 |
TWI332939B (en) | 2010-11-11 |
CN1784377A (zh) | 2006-06-07 |
IL171650A (en) | 2011-02-28 |
TW200503669A (en) | 2005-02-01 |
JP4205130B2 (ja) | 2009-01-07 |
CA2525835C (en) | 2011-08-02 |
CA2525835A1 (en) | 2004-11-25 |
EP1625110A1 (en) | 2006-02-15 |
US20070093556A1 (en) | 2007-04-26 |
FI20030747A0 (fi) | 2003-05-19 |
WO2004101492A1 (en) | 2004-11-25 |
KR20060007027A (ko) | 2006-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011503122A (ja) | 4,5−ジメトキシ−1−(メチルアミノメチル)−ベンゾシクロブタンの分離 | |
JP3911545B2 (ja) | レボブピバカインとその類似体の晶出 | |
JP2008094848A (ja) | 新規な型の4−[4−[4−(ヒドロキシジフェニルメチル)−1−ピペリジニル]−1−ヒドロキシブチル]−α,α−ジメチルベンゼン酢酸及びその塩酸塩 | |
JP2020502077A (ja) | R−6−ヒドロキシ−8−[1−ヒドロキシ−2−[2−(4−メトキシフェニル)−1,1−ジメチルエチルアミノエチル]−2h−1,4−ベンゾオキサジン−3(4h)−オン塩酸塩の改良された製造法 | |
RU2167153C2 (ru) | Способ получения моногидрата ропивакаина гидрохлорида | |
JP4205130B2 (ja) | トレミフェン結晶化法 | |
JP2004521875A (ja) | 1−(アミノメチル)シクロヘキサン酢酸の調製方法 | |
AU2009336561A1 (en) | Stable R-(+)-lansoprazole amine salt and a process for preparing the same | |
AU2001278094A1 (en) | Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperindinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride | |
EP2197273B1 (en) | Process for preparing r-gossypol l-phenylalaninol dienamine | |
JP2004511476A (ja) | R(+)α−リポ酸の製造方法 | |
JP5562337B2 (ja) | ドネペジルの多形結晶及びその製造方法 | |
WO2007080470A2 (en) | A method for the purification of levetiracetam | |
JP4190288B2 (ja) | (1rs,2rs)−2−[(ジメチルアミノ)メチル]−1−(3−メトキシフェニル)シクロヘキサノールを単離および精製する方法 | |
CN109689620B (zh) | 拆分巴氯芬盐的方法 | |
JP3358281B2 (ja) | 光学活性な(z)−5−ヒドロキシ−7−デセン酸の製造法及び光学活性なジャスミンラクトンの製造法 | |
EP2072510A1 (en) | Crystalline form of azelastine | |
EA011763B1 (ru) | Способы получения венлафаксина и формы i венлафаксина гидрохлорида | |
JP5518897B2 (ja) | エプリバンセリンヘミフマラートの調製方法 | |
JPS6383056A (ja) | ジアステレオマーの分割 | |
JPH05502027A (ja) | R(+) ―テロジリン及びそれらの塩の製造方法 | |
JP2003342259A (ja) | 光学活性シスピペリジン誘導体の製造法 | |
JP2005075754A (ja) | トランス−1,2−ビス(3,5−ジメチルフェニル)−1,2−エタンジアミンの光学分割方法 | |
JPH07103115B2 (ja) | 2−(10,11−ジヒドロ−10−オキソジベンゾ〔b,f〕チエピン−2−イル)プロピオン酸の結晶化方法 | |
WO2006050633A1 (fr) | Procede et agents de dedoublement de la dl-ephedrine ou de ses derives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080909 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081007 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081015 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111024 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4205130 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111024 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121024 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121024 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131024 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |